Mayo Foundation for Medical Education and Research

Millennium Pharmaceuticals Limited

The University of Texas System

Purdue Research Foundation

Endocyte, Inc.

Lynn C Hartmann

Philip Stewart Low

Christopher Paul Leamon

Keith L Knutson

Edwin A Clark

Christopher J Krco

Kimberly R Kalli

Karen Lu

Gordon B Mills

Robert C Bast

Jeffrey L Brown

Tallessyn Grenfell-Lee

Andrew I Damokosh

Natalia Iartchouk

James J Stec, Ii

Phil Ronald Ellis

This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FR&#x3b1; immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors.

Immunity to folate receptors

The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of 'sensitivity markers.' These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of 'resistance markers.' These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.

Compositions and methods for the identification, assessment, prevention and therapy of human cancers

The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.

Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer

Growing community of inventors

Rochester, MN, United States of America

Lynn C Hartmann